Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

UNC Libraries(2022)10.17615/4pex-cz68Source: DataRank Database

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection is a research paper published in UNC Libraries (2022). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.00)OA: greenTopics (47)IDs (PubMed, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (26)

M.D. Hughes,M.C. Choudhary,R. Deo,J. Ritz,D.A. Wohl

Live enrichment

PubMed:19910364 OpenAlex:https://openalex.org/W4291173201

National Institutes of Health

Grant: 5UM1AI068634-09

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)

National Institutes of Health

Grant: 3UM1AI068636-14S2

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/

National Institutes of Health

Grant: 5P30AI060354-18

Harvard University Center for AIDS Research

National Institutes of Health

Grant: 3UM1AI106701-12S1

AIDS Clinical Trial Group Laboratory Center

FWCI

0.00

Citation Percentile

0.1%

greenLicense: CC BY NC ND

repositoryhttps://doi.org/10.17615/4pex-cz68

https://doi.org/10.1016/j.xcrm.2022.100678

https://doi.org/10.1101/2021.12.25.21268211

https://www.medrxiv.org/content/medrxiv/early/2021/12/30/2021.12.25.21268211.full.pdf

https://dx.doi.org/10.17615/4pex-cz68

Fields of Study

SARS-CoV-2 and COVID-19 Research0301 basic medicine03 medical and health sciences

Keywords

Monoclonal antibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakAntibodyMedicineImmunologyPathologyInfectious disease (medical specialty)OutbreakDiseaseBiomedical and clinical sciencesCoronaviruses610mAbsAntibodies, Monoclonal, HumanizedAntibodiesCOVID therapiesArticleresistanceBiodefenseReport616MonoclonalHumansHumanizedNeutralizingCOVIDSARS-CoV-2viral cultureCOVID-19Antibodies, MonoclonalAntibodies, NeutralizingCOVID-19 Drug TreatmentEmerging Infectious DiseasesInfectious DiseasesGood Health and Well BeingMedical MicrobiologyPOSITIVES study teamACTIV-2/A5401 Study Teammonoclonal antibodiesInfectionBiotechnology

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Zero hunger